The twenty-ninth case of a carcinosarcoma of the urinary bladder is reported, although the diagnosis in 8 of the cases previously reported has been questioned by other authors. The microscopic features and pitfalls in histologic diagnosis are discussed. The tumor occurs predominantly i n elderly men
Urinary bladder tumors following cyclophosphamide therapy: A report of two cases with a review of the literature
โ Scribed by Samra, Yechezkiel ;Hertz, Marjorie ;Lindner, Arieh
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 406 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
โฆ Synopsis
Sterile hemorrhagic cystitis following cyclophosphamide (Cph) therapy is a relatively frequent and well-documented phenomenon.
O n the other hand, cancer of the urinary bladder associated with Cph therapy is rarely observed. We present two cases and summarize 32 patients reported in the literature.
Thirty patients had malignant disease elsewhere, 27 of them nonsolid tumors. The other four patients received treatment with Cph for nonmalignant disease (systemic lupus erythe-matosus-3; rheumatoid arthritis-I). The bladder tumor developed several months to years after treatment. In 20 patients hemorrhagic cystitis antedated the tumors. We conclude that hemorrhagic cystitis in patients on Cph therapy should indicate at least temporary withdrawal of the drug. The decision to resume treatment should be taken with extreme caution considering the risk of the development of bladder cancer.
๐ SIMILAR VOLUMES
Fatal cardiomyopathy developed in two patients receiving cyclophosphamide in preparation for bone marrow transplantation. Both patients had normal EKGs prior to receiving cyclophosphamide in total doses of 168 mg/kg (case 1) and 144 mgkg (case 2) and subsequently developed loss of voltage and ST-T w
## Abstract ## Background The antiproliferative effect of the somatostatin analogue, octreotide, on metastatic carcinoid tumors is poorly understood. Partial tumor regression seen radiogaphically has been reported with the use of octreotide therapy for neuroendocrine tumors. Complete regression of